- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA ...
PALO ALTO, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, and QED Therapeutics, the ...
- In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained increases in annualized height velocity (AHV), with a mean change from ...
– TransCon CNP is designed to address all aspects of achondroplasia by providing continuous exposure to C-type natriuretic peptide (CNP) at safe and effective levels – COPENHAGEN, Denmark, July 18, ...
CARLSBAD, Calif., Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large ...
COPENHAGEN, Denmark, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical ...
BridgeBio licensed the exclusive Japanese rights to develop and sell an experimental dwarfism drug to Tokyo-based pharma firm Kyowa Kirin, firms said earlier this week. Terms of the deal call for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback